Soligenix Eyes Rapid Bundibugyo Virus Vaccine Development Amid Congo Outbreak
Event summary
- Soligenix and University of Hawaiʻi researchers highlight existing platform compatibility for Bundibugyo virus vaccine development.
- ThermoVax® platform has demonstrated thermostability and efficacy in filovirus vaccines, including Ebola, Sudan, and Marburg.
- Ongoing Bundibugyo virus outbreak in Congo declared a Public Health Emergency of International Concern by WHO on May 16, 2026.
- Soligenix holds Orphan Drug Designation for Sudan and Marburg virus vaccines from the FDA.
The big picture
Soligenix's ability to rapidly adapt its ThermoVax® platform to the Bundibugyo virus outbreak underscores the strategic advantage of thermostable vaccines in global health crises. The company's existing collaborations and FDA designations position it to potentially fill a critical gap in filovirus vaccine availability, particularly in regions with limited cold-chain infrastructure. The ongoing outbreak in Congo highlights the urgent need for such solutions, as current approved vaccines for Ebola require stringent storage conditions.
What we're watching
- Development Timeline
- The pace at which Soligenix can secure funding and advance Bundibugyo virus vaccine development will determine its market readiness.
- Regulatory Pathway
- Whether Soligenix can leverage its Orphan Drug Designation to expedite clinical trials and approvals for the new vaccine.
- Market Differentiation
- How Soligenix's thermostable vaccine technology will compete against existing ultra-low cold-chain vaccines for filoviruses.